Home » Newsletters » BioWorld Science

BioWorld Science

July 7, 1997

View Archived Issues

SmithKline Beecham and Nycomed disclose hemoregulatory compounds

Pharmacia & Upjohn discloses agents for diabetes

Antimalarial agents from Roche

Selective dopamine autoreceptor agonists prepared by American Home Products

HIV protease inhibitors described by Searle

Synaptic and Merck & Co. prepare selective human alpha1A-adrenoceptor antagonists

MMP/TNF-alpha inhibitors from Abbott

Inhibitors of tyrosine kinase disclosed by Pharmacia & Upjohn

Garlic has beneficial effects in model of volume overload heart failure

Lifecore Biomedical to distribute LifeCell's AlloDerm in U.S.

Sublingual captopril and nifedipine compared in patients with hypertensive crises

RPR licenses Dilacor XR to Watson

Proteoglycan synthesis increased by rhBMP-2

Update on Alliance/Hoechst Marion Roussel agreement for LiquiVent

Suppressive effect of KE-298 on MMP production

Phase I results reported for Cortecs' oral insulin

Japanese companies focus on overseas development

Company profile: The Medicines Company

Prostacyclin derivative in development for skin ulcers

Summary of perospirone clinical trials

Hemodialyzer efficacy established in patients

Double identity of Bcl-2 protein described

Preliminary results reported for Cortecs' Flustat

Phase III trials show significant positive effect for sertindole on negative symptoms

Oxford Molecular Group enters drug design agreement with Dainippon

Faulding forms Faulding Soltec DDS

Novopharm granted final approval by U.S. Federal Court to market generic Zantac

Duloxetine not different from placebo in double-blind depression study

Preliminary efficacy and safety studies with panamesine in schizophrenia

Vysis' TriGen approved in France

Effects of befloxatone on psychomotor performance and memory in the elderly

VX-740: new lead antiinflammatory compound from Vertex/HMR

New agents for tachycardia from CV Therapeutics

New cardiovascular agent in development at CV Therapeutics

Agent for restenosis in preclinical development at CV Therapeutics